Immunotherapy plus chemotherapy for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new immunotherapy drug (cemiplimab) combined with chemotherapy for advanced squamous lung cancer. The treatment is chosen based on a blood test that measures a natural body enzyme, which may help predict how well the chemotherapy works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced squamous non-small cell lung cancer (a type of lung cancer).
- You must not have had chemotherapy or other cancer drugs for your advanced disease.
- You must be in good enough health to be up and about (ECOG performance status 0 or 1).
- You must have a tumor sample that shows a certain protein called PD-L1.
- You must not have untreated or symptomatic brain metastases.
- You must not have active autoimmune diseases like lupus or Crohn's disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of treatments (an immunotherapy drug called cemiplimab plus chemotherapy) for people with advanced lung cancer that has not been treated yet and shows a high PD-L1 level. The study also looks at a specific blood marker to see if it predicts how the cancer responds, aiming to avoid rapid growth (hyperprogression).
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
Hear when a new Advanced Squamous Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.